VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal Study
March 26, 2020 07:54 ET
|
Vascular Biogenics Ltd.
OVAL independent Data Safety Monitoring Committee (DSMC) reviewed un-blinded data and determined that the study has met the interim pre-specified criterion, of an absolute percentage advantage of 10%...
VBL Therapeutics Announces Year Ended December 31, 2019 Financial Results and Provides Corporate Update
March 19, 2020 07:00 ET
|
VBL Therapeutics
The OVAL Phase 3 potential-registration study of VB-111 in ovarian cancer continues as planned towards the important interim analysis in 1Q 2020VB-111 clinical program expands to include U.S....
VBL Therapeutics to Report Fourth Quarter 2019 Financial Results on March 19
March 02, 2020 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, March 02, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics Announces the Launch of a New Clinical Trial of VB-111 Combined with the Checkpoint Inhibitor, Nivolumab, in Metastatic Colorectal Cancer
February 20, 2020 08:00 ET
|
VBL Therapeutics
This clinical trial will investigate for the first time a combination of VB-111 with a checkpoint inhibitor.Pathology readouts are expected to shed light on the potential of VB-111 to turn “cold”...
VBL Therapeutics to Present at the BIO CEO & Investor Conference
February 03, 2020 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Feb. 03, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics Announces Publication of Phase 2 and Phase 3 Data of VB-111 in Recurrent Glioblastoma Supporting Continued Development in Investigator-Sponsored Study
January 08, 2020 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the publication of clinical data from the Phase 2 and Phase 3 studies of VB-111 (ofranergene...
VBL Therapeutics to Present Data on New Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting
November 21, 2019 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Nov. 21, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that data on the new investigator-sponsored Phase 2 study of VB-111 in recurrent glioblastoma...
VBL Therapeutics Announces Third Quarter 2019 Financial Results
November 14, 2019 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Nov. 14, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the third quarter ended September 30, 2019, and provided a corporate update....
VBL Therapeutics Announces New IND for an Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma
November 06, 2019 08:00 ET
|
VBL Therapeutics
Trial will be conducted at top neuro-oncology US centers, further exploring the potential of VB-111 in recurrent glioblastoma (rGBM) which is an immunologically `cold` tumor TEL AVIV, Israel, Nov. ...
VBL Therapeutics to Report Third Quarter 2019 Financial Results on November 14
October 31, 2019 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Oct. 31, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...